1. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43(2): 343-373.
5. Aravamudan B, Thompson MA, Pabelick C, et al. Cigarette smoke influences cellular metabolic signaling by deregulating mitochondrial morphology and function in human airway smooth muscle. Am J Respir Crit Care Med, 2016, 193: A1261.
[4]
6. Nagasaki T, Matsumoto H, Oguma T, et al. Both eosinophilic and neutrophilic inflammation were associated with pulmonary function in ex-smokers with asthma. Am J Respir Crit Care Med, 2016, 193: A1454.
[5]
7. Larsen K, To T, Mann R, et al. Smoking and asthma: examining factors associated with smoking in ontario teenagers with asthma. Am J Respir Crit Care Med, 2016, 193: A2022.
[6]
8. Imaoka M. Gender-specific effect of overweight and obesity on total serum IgE in adults with allergic asthma. Am J Respir Crit Care Med, 2016, 193: A7776.
[7]
9. Ahmad M, Tambe N, Thakur T, et al. Allergen sensitization and obstruction indices of allergic asthmatics with high IgE (30-700 IU/ml) in an urban population: super-obese (BMI >40 kg/m2) vs normal BMI (BMI=18-25 kg/m2). Am J Respir Crit Care Med, 2016, 193: A1433.
[8]
10. Krishnan S, Hettiaracchi D, Scharbach M, et al. Obesity and pulmonary function in school-age children with asthma. Am J Respir Crit Care Med, 2016, 193: A3797.
[9]
11. Ferrante SC, Epstein S, Nadler E, et al. Obese adipocyte-derived exosomal miRNAs targeting TGF-β signaling are associated with poor asthma control. Am J Respir Crit Care Med, 2016, 193: A4630.
[10]
12. Dixon AE, Subramanian M, Black KE, et al. Increased mucosal responses to allergen in obese compared with lean asthmatics. Am J Respir Crit Care Med, 2016, 193: A6692.
[11]
14. Wood LG, Ballantyne D, Scott H, et al. Lung function is predicted by resistin and resistin: adiponectin ratio in asthma. Am J Respir Crit Care Med, 2016, 193: A1438.
[12]
29. Zein JG, Deboer MD, Teague WG, et al. Sex hormones impact asthma severity and lung function in adult men and women. Am J Respir Crit Care Med, 2016, 193: A1436.
[13]
30. Brehm JM, Han YY, Boutaoui N, et al. Plasma vitamin D level and Th17 cytokines in children with asthma. Am J Respir Crit Care Med, 2016, 193: A2763.
[14]
31. Schedel M, Jia Y, Michel S, et al. 1, 25D3 prevents CD8+Tc2 skewing and asthma development through VDR binding changes to the Cyp11a1 promoter. Am J Respir Crit Care Med, 2016, 193: A1007.
[15]
32. Haselkorn T, Zeiger RS, Borish L, et al. Prevalence and risk factors for persistent very poorly controlled (VPC) asthma after more than a decade in the TENOR II cohort. Am J Respir Crit Care Med, 2016, 193: A1025.
[16]
33. Schreiber J, Garg K. Lack of allergy diagnostics in severe asthmatic patients in Germany. Am J Respir Crit Care Med, 2016, 193: A1443.
[17]
34. Suruki R, Carroll C, Mullerova H, et al. Prevalence of severe eosinophilic asthma in pediatric asthma patients identified in a US healthcare claims database. Am J Respir Crit Care Med, 2016, 193: A1731.
[18]
35. Bradford E, Follows R, Price R, et al. Burden of disease in severe asthma Mepolizumab population stratified by blood eosinophil count. Am J Respir Crit Care Med, 2016, 193: A6471.
[19]
36. Austin D, Pouliquen I, Yancey S, et al. A blood eosinophil count of greater than 150 cells/uL predicts sputum eosinophilia ≥ 3% in patients with severe asthma with other markers of inflammatory lung disease. Am J Respir Crit Care Med, 2016, 193: A4338.
[20]
37. Pavlidis S, Rossios C, Loza M, et al. Macrophage inflammasome activation in sputum from severe asthmatics. Am J Respir Crit Care Med, 2016, 193: A1001.
[21]
38. Palikhe NS, Laratta CR, Nahirney D, et al. Elevated levels of circulating CRTh2+CD4+T cells characterize severe asthma. Am J Respir Crit Care Med, 2016, 193: A7559.
[22]
39. Xue LZ, Hilvering B, Shrimanker R, et al. Peripheral blood CRTH2 positive cells in patients with severe asthma. Am J Respir Crit Care Med, 2016, 193: A4334.
[23]
40. Kim SR, Lee YC, Park HJ, et al. The role of mitochondrial fusion in the pathogenesis of fungus-induced severe asthma. Am J Respir Crit Care Med, 2016, 193: A6749.
[24]
41. Lee YC, Kim SR, Kim DI, et al. Morphological changes and contact of mitochondria with endoplasmic reticulum contributes to severe bronchial asthma. Am J Respir Crit Care Med, 2016, 193: A6750.
[25]
42. Kuo CHS, Pavlidis S, Loza M, et al. Sputum transcriptomics identifies co-expressed network signatures associated with FEV1 and sputum neutrophilia in severe asthmatics on oral corticosteroids. Am J Respir Crit Care Med, 2016, 193: A4623.
[26]
43. Burks AC, Naylor AD, Haspel J, et al. Normal autophagy activity is maintained in human airway epithelial cells from severe asthmatics. Am J Respir Crit Care Med, 2016, 193: A4656.
[27]
44. Hekking PP, Loza M, Meulder BD, et al. Transcriptomic fingerprints of fixed airflow limitation in adult severe asthma patients from the U-BIOPRED cohort. Am J Respir Crit Care Med, 2016, 193: A4331.
[28]
46. Orimo K, Takeyama K, Tagaya E, et al. Impact of irreversible airflow obstruction in clinical course of patients with severe atopic asthma. Am J Respir Crit Care Med, 2016, 193: A1397.
[29]
49. Kim RY, Pinkerton JW, Essilfie AT, et al. NLRP3 inflammasome-mediated, IL-1β-dependent inflammatory responses drive severe, steroid-insensitive asthma. Am J Respir Crit Care Med, 2016, 193: A1002.
[30]
50. Coverstone A, Bacharier LB, Peters M, et al. Gene expression reflective of Type 2 inflammation in the upper and lower airways of children with asthma in the Severe Asthma Research Program (SARP). Am J Respir Crit Care Med, 2016, 193: A1038.
[31]
51. Shirley DA, Pollack K, Williams S, et al. Airway epithelial cell gene expression signatures inform level of disease control among children with asthma. Am J Respir Crit Care Med, 2016, 193: A2188.
[32]
52. Soma T, Kobayashi T, Nakagome K, et al. Clinical implication of adenosine triphosphate in sputum in asthma. Am J Respir Crit Care Med, 2016, 193: A1394.
[33]
53. Panek MG, Ziolo J, Jonakowski M, et al. The effects of low- and high- expression of brain-derived neurotrophic factor on the intensity of psychopathological variables in asthma patients: apreliminary report. Am J Respir Crit Care Med, 2016, 193: A1410.
[34]
54. Himes BE, Koziol-White C, Johnson M, et al. SOCS1 and SOC3 modulate immune response in the airway smooth muscle. Am J Respir Crit Care Med, 2016, 193: A4317.
[35]
55. Ricciardolo FLM, Leone I, Sorbello V, et al. Role of acetylcholine on fibroblast-driven remodelling in asthma. Am J Respir Crit Care Med, 2016, 193: A6716.
[36]
56. Doberer D, Trejo Bittar HE, Vitari C, et al. Histologic patterns in distal lung tissue from treatment-resistant severe asthma patients. Am J Respir Crit Care Med, 2016, 193: A1298.
[37]
57. Millares L, Bermudo G, Garcia-Nunez M, et al. Bronchial microbiome in severe persistent oral corticosteroid-dependent asthma. Am J Respir Crit Care Med, 2016, 193: A1065.
[38]
58. Moore WC, Li XN, Li HS, et al. Clinical cluster phenotypes from the Severe Asthma Research Program (SARP1/2): reproducibility in SARP 3 and the importance of baseline lung function in disease stability and progression. Am J Respir Crit Care Med, 2016, 193: A7852.
[39]
59. Zeki AA, Louie S. A sub-phenotype of severe asthma patients meet criteria for Asthma-COPD Overlap Syndrome (ACOS): acomparative analysis of clinical criteria and biomarkers. Am J Respir Crit Care Med, 2016, 193: A1301.
[40]
60. Gomez JL, Crisafi G, Holm C, et al. Clinical and molecular characterization of the CHI3L1/YKL-40 severe asthma endotypes. Am J Respir Crit Care Med, 2016, 193: A4346.
[41]
61. Johansson WJ, Chow CC, Evans MD, et al. Bone density is inversely correlated with plasma levels of platelet factor 4(PF4, CXCL4) in severe asthma. Am J Respir Crit Care Med, 2016, 193: A1447.
[42]
62. Padilla A, Garcia LFDR, Stachowski JP, et al. Bronchiectasis and asthma, a fairly ordinary couple: preliminary study of 98 patients. Am J Respir Crit Care Med, 2016, 193: A1721.
[43]
63. Alsaleh H, Wilson D, Dell SDM. Spirometry-induced bronchoconstriction: a sign of severe asthma in children? Am J Respir Crit Care Med, 2016, 193: A3801.
[44]
64. Szefler SJ, Harper T, Laki I, et al. Once-daily Tiotropium Respimat？ add-on therapy improves lung function in children with severe symptomatic asthma. Am J Respir Crit Care Med, 2016, 193: A3818.
[45]
82. Chen Z, Bai FF, Han L, et al. Induction of neutrophil apoptosis by a novel monoclonal antibody against the sialic acid-binding immunoglobulin-like lectin 9(Siglec-9). Am J Respir Crit Care Med, 2016, 193: A6713.
[46]
83. Lee HH, Gil MA, Woodhouse J, et al. Pre-clinical evaluation of a potent Janus Kinase (JAK) inhibitor designed for topical delivery in severe asthma. Am J Respir Crit Care Med, 2016, 193: A6483.
[47]
84. Catley MC, Smailagic A, Rhedin M, et al. Targeting the immunological drivers of asthma with inhaled delivery of a JAK1 inhibitor. Am J Respir Crit Care Med, 2016, 193: A4836.
[48]
85. Cahill KN, Katz H, Cui J, et al. Mast cell inhibition by imatinib reduces airway reactivity and improves FEV1 in severe asthma. Am J Respir Crit Care Med, 2016, 193: A7892.
[49]
86. Andreotta PW, Rosado M, Rogers S, et al. A rat model of severe allergic asthma. Am J Respir Crit Care Med, 2016, 193: A4921.
[50]
87. Thomas M, Bold P, Bjorhall K, et al. Lung-targeted dual PI3Kγδ inhibition: evidence for a novel therapeutic strategy for multiple severe asthma phenotypes. Am J Respir Crit Care Med, 2016, 193: A7552.
[51]
88. Gavrila A, Chachi L, Tliba O, et al. Role of Interferon Regulatory Factor-1(IRF-1) in modulating steroid insensitive pathways in severe asthma. Am J Respir Crit Care Med, 2016, 193: A1005.
[52]
91. Kobayashi K, ikura M, Shiozawa A, et al. Short-term effectiveness of bronchial thermoplastyon quality of life and control in patients with severe asthma. Am J Respir Crit Care Med, 2016, 193: A1400.
[53]
3. Verhamme K, Engelkes M, Ridder MD, et al. Risk factors of severe asthma exacerbations: a real world study. Am J Respir Crit Care Med, 2016, 193: A1712.
[54]
4. Wongtrakoo C, Jia DW, Grooms K, et al. Nicotine-induced airway hyperresponsiveness may be due to inappropriate lynx1 levels in airway smooth muscle cells. Am J Respir Crit Care Med, 2016, 193: A2481.
[55]
13. To M, Ogura N, Mikami S, et al. The potential association between adipocytokine and steroid insensitivity in obese asthmatic patients. Am J Respir Crit Care Med, 2016, 193: A7777.
[56]
15. To M, Ogura N, Mikami S, et al. Clinical characteristics of obese asthmatic patients: obese asthmatic patients need more frequent unscheduled visits and rescue uses of corticosteroids. Am J Respir Crit Care Med, 2016, 193: A7778.
[57]
16. Eldeirawi K, Persky V, Kunzweiler C, et al. Associations of residence near primary traffic arterials with asthma and wheezing in a sample of Mexican American children. Am J Respir Crit Care Med, 2016, 193: A2766.
[58]
17. Prunicki M, Zhou XY, Schurz T, et al. T regulatory cell levels in asthmatic children correlate with yearly ambient air pollution levels using single-cell mass spectrometry. Am J Respir Crit Care Med, 2016, 193: A2599.
[59]
18. Rider CF, Hirota JA, Carlsten C. Effects of particulate matter exposure on glucocorticoid responsiveness in human airway epithelial cells. Am J Respir Crit Care Med, 2016, 193: A7930.
[60]
19. Cadena LH, Montiel PI, Del Rio Navarro BE, et al. Airway inflammation and oxidative stress as a response to exposure to PM2.5 in adolescents with and without asthma in Mexico City. Am J Respir Crit Care Med, 2016, 193: A2772.
[61]
20. Romero Rivero KM, Checkley W, Chen C, et al. Effects of long-term exposure to PM2.5 on asthma control in children: longitudinal study in a peri-urban community in Lima, Peru. Am J Respir Crit Care Med, 2016, 193: A2765.
[62]
21. Kamath N, Patel N, Kose LT, et al. Characteristics of severe asthma exacerbations among inner-city women in pregnancy. Am J Respir Crit Care Med, 2016, 193: A1736.
[63]
22. Falcon-Rodriguez CI, Osornio-Vargas A, Vizcaya-Ruiz AD, et al. Inhalation of fine particles from Mexico City produce fatal asthma in a guinea pig model of allergic airways inflammation. Am J Respir Crit Care Med, 2016, 193: A1184.
[64]
23. Garcia-Alonso LI, Falcon-Rodriguez CI, Osornio-Vargas A, et al. Immunologic effect of ozone and PM2.5 from Mexico City in a guinea pig asthma model. Am J Respir Crit Care Med, 2016, 193: A3700.
[65]
24. Cruz MJ, Alvarez-Simon D, Gomez-Olles S, et al. Effects of diesel exhaust particles exposure in a murine model of asthma due to soybean. Am J Respir Crit Care Med, 2016, 193: A4922.
[66]
25. Paulin LM, Matsui E, Curtin-Brosnan J, et al. Short-term nitrogen dioxide exposure increases rescue medication use in children with asthma. Am J Respir Crit Care Med, 2016, 193: A2875.
[67]
26. Seino Y, Shimizu N, Mashima I, et al. A cluster analysis of bronchial asthma patients with depressive symptoms. Am J Respir Crit Care Med, 2016, 193: A4972.
[68]
27. Sagmen SB, Olgun S, Baykan H, et al. The impact of psychological factors on asthma patients. Am J Respir Crit Care Med, 2016, 193: A1744.
[69]
28. Comhair SAA, Baicker-McKee SM, Bleeker E, et al. Age and gender-specific protective effects of superoxide dismutase in asthma severity. Am J Respir Crit Care Med, 2016, 193: A3171.
[70]
45. Rakowski EM, Lubinsky AS. Fixed focal stenosis due to airway remodelling from severe asthma. Am J Respir Crit Care Med, 2016, 193: A3588.
[71]
47. Panariti A, Narayanan V, Baglole C, et al. Increased vascularity of the bronchial mucosa in patients with severe asthma and the role of IL-17A in angiogenesis and vascular remodeling. Am J Respir Crit Care Med, 2016, 193: A6680.
[72]
48. Gauthier M, Oriss T, Raundhal M, et al. A potential mechanism for steroid resistance in severe asthma. Am J Respir Crit Care Med, 2016, 193: A7771.
[73]
65. Szefler SJ, Rupp N, Boner A, et al. Safety and tolerability of once-daily Tiotropium Respimat？ add-on therapy in children with severe symptomatic asthma. Am J Respir Crit Care Med, 2016, 193: A3819.
[74]
66. Jabre NA, Gondor M. Effectiveness of Tiotropium in children with difficult-to-control asthma. Am J Respir Crit Care Med, 2016, 193: A3820.
[75]
67. Chen JA, Jackson DJ. Type 2 immune therapies for severe asthma: overlapping suitability leads to further questions. Am J Respir Crit Care Med, 2016, 193: A1308.
[76]
68. Weinstein SF, Ford LB, Zhang BZ, et al. Effect of Dupilumab on FEV1 and severe exacerbations in patients with uncontrolled persistent asthma: asubgroup analysis defined according to early-onset and late-onset asthma. Am J Respir Crit Care Med, 2016, 193: A6486.
[77]
69. Castro M, Wenzel SE, Corren J, et al. Dupilumab improves lung function inclusive of small airways in patients with uncontrolled persistent asthma: results from a phase 2b clinical trial. Am J Respir Crit Care Med 193; 2016: A6489.
[78]
70. Chanez P, Corren J, Castro M, et al. Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma: results from a phase 2b clinical trial. Am J Respir Crit Care Med, 2016, 193: A6491.
[79]
71. Hanania NA, Korenblat P, Chapman KR, et al. LAVOLTA Ⅰ and Ⅱ: design and baseline characteristics of two phase Ⅲ, randomized, double-Blind, placebo-controlled studies to assess the efficacy and safety of Lebrikizumab in adult patients with uncontrolled asthma. Am J Respir Crit Care Med, 2016, 193: A1318.
[80]
72. Hanania NA, Korenblat P, Corren J, et al. The effect of Lebrikizumab therapy on key Type 2 biomarkers in moderate-to-severe, uncontrolled asthma patients: apooled analysis from phase 2 trials. Am J Respir Crit Care Med, 2016, 193: A6493.
[81]
73. Li J, Kang J, Wang CZ, et al. Omalizumab responder analysis in Chinese patients with moderate-to-severe Asthma. Am J Respir Crit Care Med, 2016, 193: A1304.
[82]
74. Zierau L, Walsted ES, Backer V. Omalizumab - response in patients with severe allergic asthma in a real life setting. Am J Respir Crit Care Med, 2016, 193: A6474.
[83]
75. Tagaya E, Mizobuchi R, Kubo A, et al. Efficacy of the anti-IgE monoclonal antibody Omalizumab in patients with severe asthma complicated with eosinophilic otitis media. Am J Respir Crit Care Med, 2016, 193: A1327.
[84]
76. Hew M, Gillman A, Sutherland M, et al. Clinical effectiveness of Omalizumab in severe allergic asthma above the recommended dosing range: the Australian Xolair Registry. Am J Respir Crit Care Med, 2016, 193: A1407.
[85]
77. Tajiri T, Matsumoto H, Gon Y, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to Omalizumab in patients with severe asthma. Am J Respir Crit Care Med, 2016, 193: A6472.
[86]
78. Albers FC, Price R, Yancey S, et al. Effect of Mepolizumab in severe eosinophilic asthma patients eligible for Omalizumab treatment. Am J Respir Crit Care Med, 2016, 193: A6470.
[87]
79. Nelsen LM, Suruki R, Albers F, et al. Characterization of a severe asthma patient population with and without eosinophilic inflammation and frequent exacerbations by multiple PROs (IDEAL). Am J Respir Crit Care Med, 2016, 193: A4330.
[88]
80. Suruki R, Gunsoy N, Shin JY, et al. Evaluation of US subjects in the identification and description of severe asthma patients in a cross-sectional study-the IDEAL study. Am J Respir Crit Care Med, 2016, 193: A1730.
[89]
81. Newbold P, Wu YP, Shih V, et al. High blood eosinophil concentrations and serum biomarkers of low IL-13 pathway activation at baseline predict exacerbation rate reduction by Benralizumab for patients with moderate to severe Asthma. Am J Respir Crit Care Med, 2016, 193: A4351.
[90]
89. Hojo M, Iikura M, Suzuki M, et al. Step down strategy; Can LTRA be withdrawn safely from combination therapy with medium to high dose of ICS/LABA, Tiotropium Bromide and LTRA in severe asthmatics? Am J Respir Crit Care Med, 2016, 193: A1322.
[91]
90. Curtiss M, Wang Y, Zhi DG, et al. Clinical symptom burden in severe asthma one year after completion of bronchial thermoplasty. Am J Respir Crit Care Med, 2016, 193: A1317.
[92]
92. Tran T, Win KN, Chan TK, et al. Effects of POST bronchial thermoplasty treatment on airway inflammation parameters: a pilot study. Am J Respir Crit Care Med 193; 2016: A2460.
[93]
93. Perez TA, Reyes JLW, Estrada EL, er al. Bronchial thermoplasty in asthmatic patients with severe fixed airflow obstruction: safety and following for one year. Am J Respir Crit Care Med, 2016, 193: A3371.
[94]
94. Herth FJ, Niven R, Torrego A, et al. Bronchial thermoplasty (BT) global registry: trial design and current patient profile. Am J Respir Crit Care Med, 2016, 193: A3387.
[95]
95. Patel S, Mathur AK, Galvani C, et al. Reduction of systemic corticosteroid requirement for severe asthma following minimally-invasive Nissen fundoplication for severe GERD. Am J Respir Crit Care Med, 2016, 193: A1411.
[96]
96. John Sutton EMS, Tsuang A, Viswanathan S, et al. Mycobiome analysis of lower airway secretions from children with fungal-sensitized severe-persistent asthma. Am J Respir Crit Care Med, 2016, 193: A1067.
[97]
97. Dilokthornsakul P, Thompson AM, Campbell JD. Asthma treatment transition and its asthma-related clinical events in patients with severe asthma. Am J Respir Crit Care Med, 2016, 193: A1723.
[98]
98. Masaki K, Fukunaga K, Kamatani T, et al. Age at onset and adherence to ICS controller therapy among severe asthmatics (Keio-SARP). Am J Respir Crit Care Med, 2016, 193: A4957.
[99]
99. Depietro M, Durden E, Fox KM, et al. Occurrence of severe asthma events and exacerbations by level of controller therapy in patients with asthma in the United States. Am J Respir Crit Care Med, 2016, 193: A2943.
[100]
100. Yii A, Lapperre T, Lim WT, et al. Medication adherence among difficult-to-treat asthmatics managed in a specialist asthma clinic. Am J Respir Crit Care Med, 2016, 193: A4959.
[101]
101. Van Der Meer AN, Pasma H, Kempenaar1 W, et al. A one-day-visit program in a specialized severe asthma center improves asthma control, quality of life and healthcare utilization after one year. Am J Respir Crit Care Med, 2016, 193: A1735.
[102]
102. Tay TR, Radhakrishna N, Hore-Lacey F, et al. Protocolised difficult asthma assessment improves asthma outcomes. Am J Respir Crit Care Med, 2016, 193: A1741.
[103]
103. Kertz L, Rivera-Spoljaric K. Identifying barriers to care and health/treatment beliefs facilitates a better understanding of uncontrolled, severe asthma in the pediatric patient. Am J Respir Crit Care Med, 2016, 193: A2167.
[104]
104. Brinkman P, Wagener AH, Hekking PP, et al. Longitudinal replication of severe asthma exhaled breath phenotypes by the U-BIOPRED electronic nose platform. Am J Respir Crit Care Med, 2016, 193: A4329.
[105]
105. Wheelock CE, Kolmert J, Lefaudeux D, et al. Non-invasive sub-phenotyping of asthma in the U-BIOPRED study by analysis of urinary lipid mediator excretion patterns. Am J Respir Crit Care Med, 2016, 193: A4632.
[106]
106. SulaimanI, Machale E, Seheult J, et al. Feedback on adherence and inhaler technique using the INCA device: a randomised control trial in severe asthma. Am J Respir Crit Care Med, 2016, 193: A1714.
[107]
107. Zavaletta V, Mummy DG, Schiebler ML, et al. Characterizing patterns of fSAD in asthma using an automated Parametric Response Map algorithm. Am J Respir Crit Care Med, 2016, 193: A2496.
